Answers are grounded in this paper and cite their sources.
The JAK2/STAT3 pathway contributes to head and neck squamous cell carcinoma (HNSCC) progression. Using a STAT3 reporter assay, we screened a panel of 79 compounds and identified lomerizine, a calcium channel blocker approved in Japan for migraine prophylaxis, as an inhibitor of reporter activity. Lomerizine reduced JAK2 and STAT3 phosphorylation in CAL-27 cells and suppressed proliferation in the HNSCC cell models tested. Ferroptosis-associated readouts and EMT-marker changes were observed in CAL-27 HNSCC cells. In cisplatin-resistant CAL-27-DDP cells, combined lomerizine and cisplatin treatment reduced cell viability compared with cisplatin alone. Target prediction, molecular docking, cellular thermal shift assay (CETSA), and CACNA1B knockdown results implicate CACNA1B as a candidate mediator of lomerizine-associated JAK2/STAT3 changes. Lomerizine treatment also reduced tumor growth in PDX and CAL-27 xenograft models. These findings support further preclinical evaluation of lomerizine in HNSCC.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: